This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.
Gilead Sciences is a top pharmaceutical company based in California, USA
Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen
Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced
Sorry, your search returned no results.
EnvisionRx announced a partnership with Gilead Sciences to provide availability to HCV infection treatments Sovaldi and Harvoni
Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program
Ono Pharmaceutical and Gilead Sciences have entered into an exclusive license agreement for the development and commercialization of ONO-4059
Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.
Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate).